VBI Vaccines Inc VBIV:NASDAQ

Last Price$1.74NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.09(4.92%)
Bid (Size)$1.74 (30)
Ask (Size)$1.77 (2)
Day Low / High$1.74 - 1.87
Volume3.6 M
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

VBI Vaccines Inc ( NASDAQ )

Price: $1.74
Change: -0.09 (4.92%)
Volume: 3.6 M
4:00PM ET 1/21/2022
 
 

BioXcel Therapeutics Inc ( NASDAQ )

Price: $16.68
Change: -0.75 (4.30%)
Volume: 462.7 K
4:00PM ET 1/21/2022
 
 

Lexicon Pharmaceuticals Inc ( NASDAQ )

Price: $3.15
Change: -0.10 (3.08%)
Volume: 530.5 K
4:00PM ET 1/21/2022
 
 

Deciphera Pharmaceuticals Inc ( NASDAQ )

Price: $8.04
Change: -0.11 (1.35%)
Volume: 1.3 M
4:00PM ET 1/21/2022
 
 

Chimerix Inc ( NASDAQ )

Price: $5.51
Change: -0.07 (1.25%)
Volume: 838.5 K
4:00PM ET 1/21/2022
 

Read more news Recent News

VBI Vaccines Starts Dosing in Second Phase 2 Hepatitis B Virus Trial
10:34AM ET 1/05/2022 MT Newswires

VBI Vaccines (VBIV) on Wednesday said that dosing has commenced in the second phase 2a/2b study evaluating VBI-2601 candidate as an add-on therapy to the...

--Jefferies Analyst Starts VBI Vaccines at Buy, Adjusts Price Target to $6 From $7
7:24AM ET 12/29/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

VBI Vaccines Files New-Drug Submission to Health Canada for 3-Antigen Hepatitis B Vaccine Candidate
9:14AM ET 12/09/2021 MT Newswires

VBI Vaccines (VBIV) said Thursday it has filed a new-drug submission to Health Canada for the company's 3-antigen prophylactic hepatitis B vaccine...

VBI Vaccines Says FDA Approves PreHevbrio for Hepatitis B in Adults; Shares Rise
9:12AM ET 12/01/2021 MT Newswires

VBI Vaccines (VBIV) said Wednesday that the Food and Drug Administration has approved PreHevbrio for the prevention of infection caused by hepatitis B...

Company Profile

Business DescriptionVBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA. View company web site for more details
Address222 3rd Street
Cambridge, Massachusetts 02142
Phone+1.617.830.3031
Number of Employees112
President, Chief Executive Officer & DirectorJeff Baxter
CFO, Director & Head-Business DevelopmentChristopher McNulty
Chief Medical OfficerFrancisco Diaz-Mitoma
Chief Scientific OfficerDavid Evander Anderson

Company Highlights

Price Open$1.80
Previous Close$1.83
52 Week Range$1.74 - 4.83
Market Capitalization$447.7 M
Shares Outstanding257.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/01/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.26
Beta vs. S&P 500N/A
Revenue$3.4 M
Net Profit Margin-9,290.20%
Return on Equity-39.02%

Analyst Ratings as of 06/10/2021

Buy
3
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset